I’ve written previously about sequential PTAB challenges to the same patent, but the dispute between Coherus Biosciences Inc. and AbbVie Biotechnology Ltd. has engendered six Inter Partes Review proceedings against the same Humira patent, four of which are pending and awaiting institution decisions.¬†Coherus’s aggressive use of PTAB proceedings to challenge¬†Humira patents shows that biosimilar applicants … Continue reading this entry